A practical reference on NMN: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Solid form; desiccated and protected from light |
| Solubility class | Freely soluble in water | Polar compound; solubility depends on temperature and pH |
| Common analytical method | HPLC-UV | Often confirmed with LC-MS/MS for identity and purity |
| Purity assessment | 95% or higher typical research grade | Values vary by supplier and analytical method |
| Regulatory status | Varies by country | Not approved as a drug; US FDA has stated exclusion from dietary supplement definition |
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Laboratory identification of NMN usually relies on chromatographic separation coupled with ultraviolet or mass spectrometric detection. High-performance liquid chromatography with UV absorbance can quantify the compound against a reference standard, while liquid chromatography-tandem mass spectrometry offers lower detection limits and better specificity in complex matrices. Nuclear magnetic resonance spectroscopy can confirm structural identity and isomeric form. Ion chromatography or capillary electrophoresis may be used to identify counterions such as sodium. Method validation includes accuracy, precision, linearity, and limits of detection.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally stored cold, often at minus twenty degrees Celsius or lower, in a desiccated container protected from light. Aqueous solutions tend to be less stable than dry powder because hydrolysis and dephosphorylation can occur, potentially forming nicotinamide riboside or other degradation products. Stress studies may expose samples to heat, acid, base, oxidation, and strong light to identify likely degradation pathways. Results from such studies help define shelf life and handling recommendations, though exact stability depends on formulation and packaging.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Specific site targeting requires the residues to also be modified to be accessible and chemically bioorthogonal to the rest of the silk protein. Cytosine residues are commonly used for this type of conjugation through a Michael addition, but they tend to undergo exchange reactions which makes them unstable for long durations in a biological environment. These two methods are rather outdated but have been useful in validating the fact that 4RepCT can be tuned in the important areas of cellular adhesion, antimicrobial potency, and the type of molecule or drug attached to it. Later azide functional groups were conjugated to the N-terminal of a dragline silk protein using EDC/NHS coupling, yielding glycopolymer-conjugated films with enhanced cell adhesion and DNA-silk chimeras with controllable micro-architectures. Armed with this, the researchers in this study investigated the incorporation of 3 L-Aha residues into 4RepCT, yielding
== Adverse effects == Cefodizime has been shown to be generally well tolerated in drug trials and its adverse effects are mainly gastrointestinal or dermatological. Gastrointestinal adverse effects were observed in 2.4% of patients during clinical trials and included: diarrhea, nausea, vomiting, and elevated transaminases. Allergic symptoms were observed in 1.1% of patients and include: exanthema, urticaria, and pruritus. Other adverse effects observed include local site reactions, pain at site of injection, and phlebitis.
The half-life of uranium-236 is too short for it to be primordial, though it has been identified as an extinct progenitor of its alpha decay daughter, thorium-232. Uranium-236 occurs in spent nuclear fuel when neutron capture on 235U does not induce fission, or as a decay product of plutonium-240. Uranium-236 is not fertile, as three more neutron captures are required to produce fissile 239Pu, and is not itself fissile; as such, it is considered long-lived radioactive waste. Uranium-234 is a member of the uranium series and occurs in equilibrium with its progenitor, 238U; it undergoes alpha decay with a half-life of 245,500 years and decays to lead-206 through a series of relatively short-lived isotopes. Uranium-233 undergoes alpha decay with a half-life of 160,000 years and, like 235U, is fissile. It can be bred from thorium-232 via neutron bombardment, usually in a nuclear reactor; this process is known as the thorium fuel cycle. Owing to the fissility of 233U and the greater natural abundance of thorium (three times that of uranium), 233U has been investigated for use as nuclear fuel as a possible alternative to 235U and 239Pu, though is not in widespread use as of 2022. The decay chain of uranium-233 forms part of the neptunium series and ends at nearly-stable bismuth-209 (half-life 2.01×1019 years) and stable thallium-205. Uranium-232 is an alpha emitter with a half-life of 68.9 years. This isotope is produced as a byproduct in production of 233U and is considered a nuisance, as it is not fissile and decays through short-lived alpha and gamma emitters such as 208Tl.
The stage was also an important part of Thomas's life from 1929 to 1934, as an actor, writer, producer and set painter. He took part in productions at Swansea Grammar School, and with the YMCA Junior Players and the Little Theatre, which was based in the Mumbles. It was also a touring company that took part in drama competitions and festivals around South Wales. Between October 1933 and March 1934, for example, Thomas and his fellow actors took part in five productions at the Mumbles theatre, as well as nine touring performances. Thomas continued with acting and production throughout his life, including his time in Laugharne, South Leigh and London (in the theatre and on radio), as well as taking part in nine stage readings of Under Milk Wood. The Shakespearian actor, John Laurie, who had worked with Thomas on both the stage and radio thought that Thomas would "have loved to have been an actor" and, had he chosen to do so, would have been "Our first real poet-dramatist since Shakespeare." Painting the sets at the Little Theatre was just one aspect of the young Thomas's interest in art. His own drawings and paintings hung in his bedroom in Cwmdonkin Drive, and his early letters reveal a broader interest in art and art theory. Thomas saw writing a poem as an act of construction "as a sculptor works at stone," later advising a student "to treat words as a craftsman does his wood or stone...hew, carve, mould, coil, polish and plane them..." Throughout his life, his friends included artists, both in Swansea and in London, as well as in America.
Sources: en.wikipedia.org
Roderick S. Bucknell analysed four versions of the twelve nidanas, to explain the existence of various versions of the pratitya-samutpada sequence. The twelvefold version is the "standard version", in which vijnana refers to sensual consciousness. According to Bucknell, the "standard version" of the twelve nidanas developed out of an ancestor version, which in turn was derived two different versions that understand consciousness (vijñana) and name and form (namarupa) differently.
The first Lower Saxon parliament or Landtag met on 9 December 1946. It was not elected; rather it was established by the British Occupation Administration (a so-called "appointed parliament"). That same day the parliament elected the Social Democrat, Hinrich Wilhelm Kopf, the former Hanoverian president (Regierungspräsident) as their first minister-president. Kopf led a five-party coalition, whose basic task was to rebuild a state afflicted by the war's rigours. Kopf's cabinet had to organise an improvement of food supplies and the reconstruction of the cities and towns destroyed by Allied air raids during the war years. Hinrich Wilhelm Kopf remained – interrupted by the time in office of Heinrich Hellwege (1955–1959) – as the head of government in Lower Saxony until 1961. The greatest problem facing the first state government in the immediate post-war years was the challenge of integrating hundreds of thousands of refugees from Germany's former territories in the east (such as Silesia and East Prussia), which had been annexed by Poland and the Soviet Union. Lower Saxony was at the western end of the direct escape route from East Prussia and had the longest border with the Soviet Zone. On 3 October 1950 Lower Saxony took over the sponsorship of the very large number of refugees from Silesia. In 1950 there was still a shortage of 730,000 homes according to official figures.
=== Not marketed === ACT-335827 – selective OX1 antagonist Almorexant (ACT-078573) – dual OX1 and OX2 antagonist – half-life 13–19 hours – development of the drug was abandoned in January 2011 EMPA – selective OX2 antagonist Filorexant (MK-6096) – dual OX1 and OX2 antagonist – half-life 3–6 hours – development was discontinued in 2015 GSK-649868 (SB-649868) – dual OX1 and OX2 antagonist – was in development for potential use in sleep disorders JNJ-10397049 – selective OX2 antagonist RTIOX-276 – selective OX1 antagonist SB-334867 – first non-peptide selective OX1 antagonist – has been shown to produce sedative and anorectic effects in animals SB-408124 – selective OX1 antagonist TCS-OX2-29 – first non-peptide selective OX2 antagonist
Sources: en.wikipedia.org
a physician advises against the discontinuation of medications that can interfere with test results or cause medical complications; a patient has severe skin conditions such as widespread eczema or a patient has such a high sensitivity level to suspected allergens that any administration of those allergens might result in potentially serious side effects.
A variety of geologic and environmental settings have been proposed for an origin of life. These theories are often in competition with one another as there are many views of prebiotic compound availability, geophysical setting, and early life characteristics. The first organism on Earth likely differed from LUCA. Between the first appearance of life and where all modern phylogenies began branching, an unknown amount of time passed, with unknown gene transfers, extinctions, and adaptation to environmental niches. Modern phylogenies provide more genetic evidence about LUCA than about its precursors.
Oxazepam is a short-to-intermediate-acting benzodiazepine. Oxazepam is used for the treatment of anxiety, insomnia, and to control symptoms of alcohol withdrawal syndrome. It is a metabolite of diazepam, prazepam, and temazepam, and has moderate amnesic, anxiolytic, anticonvulsant, hypnotic, sedative, and skeletal muscle relaxant properties compared to other benzodiazepines. It was patented in 1962 and approved for medical use in 1964.
Sources: en.wikipedia.org
Solid NMN is commonly stored frozen at about minus 20 degrees Celsius, sealed against moisture, and protected from light. Solutions are typically prepared fresh because they can degrade more quickly. Specific storage conditions can vary by supplier and intended use.
Common methods include high-performance liquid chromatography with ultraviolet detection and liquid chromatography with mass spectrometry. Nuclear magnetic resonance spectroscopy can provide structural confirmation. Reported purity depends on the method and the reference standards used.
NMN is not approved as a therapeutic drug in the United States, European Union, or Japan. Its legal status as a supplement or food ingredient varies by jurisdiction. In the United States, the FDA has stated that NMN is excluded from the dietary supplement definition, though enforcement has been debated.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.